Anebulo Pharmaceuticals Net Worth
Anebulo Pharmaceuticals Net Worth Breakdown | ANEB |
Anebulo Pharmaceuticals Net Worth Analysis
Anebulo Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Anebulo Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Anebulo Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Anebulo Pharmaceuticals' net worth analysis. One common approach is to calculate Anebulo Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Anebulo Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Anebulo Pharmaceuticals' net worth. This approach calculates the present value of Anebulo Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Anebulo Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Anebulo Pharmaceuticals' net worth. This involves comparing Anebulo Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Anebulo Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Anebulo Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Anebulo Pharmaceuticals' net worth research are outlined below:
| Anebulo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Anebulo Pharmaceuticals has high historical volatility and very poor performance | |
| Anebulo Pharmaceuticals may become a speculative penny stock | |
| Net Loss for the year was (8.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (8.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Anebulo Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN |
Anebulo Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Anebulo Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anebulo Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Anebulo Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anebulo Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anebulo Pharmaceuticals backward and forwards among themselves. Anebulo Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Anebulo Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 51.0 | Jpmorgan Chase & Co | 2024-06-30 | 10.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | 22nw, Lp | 2024-06-30 | 5.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 798.4 K | Lvw Advisors, Llc | 2024-09-30 | 641 K | Nantahala Capital Management, Llc | 2024-09-30 | 511.1 K | Ikarian Capital, Llc | 2024-09-30 | 157.9 K | Vanguard Group Inc | 2024-09-30 | 154 K |
Follow Anebulo Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.79 M.Market Cap |
|
Project Anebulo Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.01) | (2.11) | |
| Return On Capital Employed | (2.18) | (2.07) | |
| Return On Assets | (2.01) | (2.11) | |
| Return On Equity | (2.15) | (2.04) |
When accessing Anebulo Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Anebulo Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Anebulo Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Anebulo Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anebulo Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Anebulo Pharmaceuticals' management manipulating its earnings.
Evaluate Anebulo Pharmaceuticals' management efficiency
Anebulo Pharmaceuticals has return on total asset (ROA) of (0.6597) % which means that it has lost $0.6597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.138) %, meaning that it created substantial loss on money invested by shareholders. Anebulo Pharmaceuticals' management efficiency ratios could be used to measure how well Anebulo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -2.11. The current year's Return On Capital Employed is expected to grow to -2.07. At present, Anebulo Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 510.5 K, whereas Total Assets are forecasted to decline to about 3.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.15 | 0.14 | |
| Tangible Book Value Per Share | 0.15 | 0.14 | |
| Enterprise Value Over EBITDA | (8.21) | (7.80) | |
| Price Book Value Ratio | 18.15 | 19.06 | |
| Enterprise Value Multiple | (8.21) | (7.80) | |
| Price Fair Value | 18.15 | 19.06 | |
| Enterprise Value | 66.1 M | 115.6 M |
Anebulo Pharmaceuticals benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Return On Equity (1.14) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anebulo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anebulo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anebulo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anebulo Pharmaceuticals time-series forecasting models is one of many Anebulo Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Anebulo Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Anebulo Pharmaceuticals Earnings per Share Projection vs Actual
Anebulo Pharmaceuticals Corporate Management
| Rex CFA | CFO Sec | Profile | |
| Daniel George | Acting Officer | Profile | |
| Scott Anderson | Head Affairs | Profile | |
| Kenneth Cundy | Chief Officer | Profile |
Already Invested in Anebulo Pharmaceuticals?
The danger of trading Anebulo Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anebulo Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anebulo Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anebulo Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (0.66) | Return On Equity (1.14) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.